| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 107.2MM | +3% |
| Gross Profit | 35.9MM | -9% |
| Cost Of Revenue | 71.3MM | +11% |
| Operating Income | -4MM | -279% |
| Operating Expenses | 39.9MM | +7% |
| Net Income | -9.6MM | - |
| R&D | 15.3MM | +9% |
| G&A | 13.2MM | +2% |
| Marketing | 11.4MM | +11% |
| Amortization | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024. The latest generation CyberKnife® and Radixact® platforms provide medical care teams with the technology necessary for expanding the curative power of radiation therapy and delivering on the focus of this year's congress, bridging the care gap. The European Society for Radiotherapy and Oncology's (ESTRO) annual me
Accuray Incorporated (NASDAQ: ARAY) announced today that as part of its commitment to advancing patient care the company has opened a new training center in Genolier, Switzerland, that will serve as the European education hub for radiosurgery and radiotherapy product training, and sharing of best practices and innovative techniques using the latest model Accuray CyberKnife® and Radixact® Radiation Treatment Delivery Systems and Accuray Precision® Treatment Planning System. The Genolier based cen
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 1, 2024.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
In this article, we will take a look at the 13 best penny stocks to buy according to billionaire Ken Griffin. To see more such companies, go directly to 5 Best Penny Stocks to Buy According to Billionaire Ken Griffin. The markets were off to an impressive start in 2024, driven by expectations that the […]
If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Accuray Incorporated...
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to
Accuray's (ARAY) solid product demand raises optimism about the stock.
Risk and reward are the watchwords of all investing, and that’s especially true in the stock markets. Business cycles turn up and down, economies rise and fall, companies succeed or fail on idiosyncratic grounds – it takes a special kind of risk tolerance to try and read the tea leaves scattered on Wall Street. But the savvy investor knows that tolerating risk is the key to success – and that few stock segments offer a better reward potential, for the risk involved, than the penny stocks. These